Search

Your search keyword '"Kaji, Kosuke"' showing total 598 results

Search Constraints

Start Over You searched for: Author "Kaji, Kosuke" Remove constraint Author: "Kaji, Kosuke"
598 results on '"Kaji, Kosuke"'

Search Results

1. VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis

7. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis

8. Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis.

10. Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus‐related liver cirrhosis

12. Impact of the COVID‐19 pandemic on the treatment of acute cholangitis caused by choledocholithiasis: A single‐center retrospective study in Japan

13. Role of Epiregulin on Lipopolysaccharide-Induced Hepatocarcinogenesis as a Mediator via EGFR Signaling in the Cancer Microenvironment

16. Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats

18. Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis

19. Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis

20. The Effects of Entecavir and Tenofovir Alafenamide Fumarate Treatment on Renal Function in Japanese Elderly Patients with Chronic Hepatitis B

21. Plasma copeptin concentration is a predictor of tolvaptan efficacy in patients with hepatic ascites

22. APRI has Utility as a Biomarker of COVID‐19 Severity in Patients with Nonalcoholic Fatty Liver Disease

25. ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis.

26. Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B.

27. Hemoglobin and Endotoxin Levels Predict Sarcopenia Occurrence in Patients with Alcoholic Cirrhosis

29. Drug Delivery with Hyaluronic Acid-Coated Polymeric Micelles in Liver Fibrosis Therapy

30. Hemoglobin levels as a surrogate marker of sarcopenia in patients with liver cirrhosis

33. Aspartate aminotransferase to platelet ratio index has utility as a biomarker of COVID‐19 severity in patients with nonalcoholic fatty liver disease.

34. Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity

35. The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure

36. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan

38. Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study

39. Diagnostic yield of liquid‐based cytology in serial pancreatic juice aspiration cytological examination

40. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis

41. Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib

45. レンバチニブは実験的肝線維症において肝星細胞の活性化と類洞毛細血管化を阻害することにより肝線維化を抑制する。

46. Efficacy of a dedicated plastic stent in endoscopic ultrasound-guided hepaticogastrostomy during the learning curve: cumulative multi-center experience

47. Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis

48. <Articles>A Study of Gion and the Adopted Daughters who were Separated from Their Parents for Life in the Late Edo Period (Special Issue : Gender)

50. Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis

Catalog

Books, media, physical & digital resources